-

Innovaderm Research Welcomes Dr Juan Gabriel Ovalles Bonilla, MD, PhD as Medical Rheumatology Lead, Expanding its Reach into this Field

MONTREAL--(BUSINESS WIRE)--Innovaderm Research, a leader in dermatological research, is pleased to announce the appointment of Juan Gabriel Ovalles Bonilla, MD, PhD, a seasoned Europe-based board-certified rheumatologist, to its team. Dr Ovalles’ experience and expertise marks Innovaderm’s expansion into the field of rheumatology, furthering its commitment to advancing research and patient care in systemic autoimmune disease.

Dr Ovalles brings 12+ years of clinical research expertise and a background in both general and pediatric rheumatology to Innovaderm. As a distinguished member of the Spanish Society of Rheumatology, his specialist knowledge spans systemic immune-mediated diseases, inflammatory arthropathies, juvenile rheumatic conditions, crystal-deposition diseases, osteoarthritis and osteoporosis.

Dr Robert Bissonnette, MD, PhD, CEO and Founder of Innovaderm, said: “We are thrilled to welcome Dr Ovalles to Innovaderm Research. His expertise will be a tremendous asset to our team as we continue to advance our research and improve patient outcomes in both dermatology and rheumatology.”

Innovaderm’s expansion reflects the need for a specialized CRO in rheumatology. The company is backed by the commonalities shared with dermatology, and already has well-established relationships with key physicians and clinical trial leaders in Europe, North America, LATAM and APAC, making it well-placed to offer robust clinical, drug developmental, regulatory, and medical knowledge to both disciplines.

For more information about our rheumatology resources please visit: https://innovaderm.com/rheumatology/

Innovaderm Research Inc.

Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.

Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

Industry:

Innovaderm Research Inc.

Release Versions
English

Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

More News From Innovaderm Research Inc.

Indero CRO and the World Scleroderma Foundation Announce Strategic Collaboration to Advance Early Therapeutic Intervention in Systemic Sclerosis

MONTREAL--(BUSINESS WIRE)--Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial designed to evaluate multiple investigational medicinal products (IMPs) for patients meeting VEDOSS criteria. This trial aims to intervene at the earliest stages of systemic sclerosis to improve long-term patient outcomes. This partnership brings together 2 leaders in thei...

Indero Named Best Employer by Mercer

MONTREAL--(BUSINESS WIRE)--Indero, a global CRO specializing in dermatology and rheumatology, has been honored by Mercer, recognizing its excellence as a Best Employer. Indero is proud of its long-term commitment to building a workplace culture defined by trust, fairness, and meaningful employee experiences and believes this distinction reflects its positive impact in 2025. The Best Employers in Canada – Powered by Mercer certification program recognizes organizations that consistently deliver...

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...
Back to Newsroom